Reports Q1 revenue $832.06M , consensus $902.28M. We generated strong first-quarter performance, with double-digit growth for KRYSTEXXA and UPLIZNA, and saw positive trends in TEPEZZA’s leading indicators as we exited the first quarter," said Tim Walbert, chairman, president and chief executive officer, Horizon. "Importantly, we announced positive topline results from our TEPEZZA clinical trial in low CAS and long-duration TED patients, as well as received FDA approval for an update to the TEPEZZA indication that reinforces the potential benefit of TEPEZZA, regardless of disease activity or duration. These important events will help us to ease the access burden so all eligible patients can benefit from TEPEZZA. I am extremely proud of what we have accomplished in a few short months and believe we are well positioned as we prepare to become part of Amgen."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HZNP:
- Horizon Pharma put volume heavy and directionally bearish
- TD Cowen merger specialist to hold an analyst/industry conference call
- Viridian Therapeutics initiated with an Overweight at Wells Fargo
- Horizon Therapeutics announces FDA approval of Tepezza indication update
- Horizon announces results from Tepezza trial in patients with CAS, TED
